Drug · Small Molecule

Mifamurtide

CI-DRUG-00000789Explore in graph →CHEMBL2107354 Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	Osteosarcoma	Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.	approved	Mar 6, 2009	ema

Data updated 7 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 2	2	1	0	3	1	EU	Mar 6, 2009	2014-10

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 6 hours agoSource updated unknown

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (6)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–6 of 6 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07787429	Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma(Dragonfly)	recruiting	Phase 2	40	Anna RaciborskaOTHER	1	Aug 26, 2026	clinicaltrials
NCT03643133	Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients(SARCOME13)

Molecule

Record

Kind: Small Molecule
Mechanism: Nucleotide-binding oligomerization domain-containing protein 2 other
Targets: 1 gene
Aliases: L-MTP-PE, Mepact, Mifamurtida, Mifamurtide, Mifamurtide sodium hydrate, Mifamurtide sodium salt monohydrate, Sodium mifamurtide

Data updated 2 days agoSource updated unknown

Identifiers

Codes (2)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L03AX15	Immunostimulants
EMA product	EMEA/H/C/000802	Mepact

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.